help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/endo-101-3-911
Endocrinology Vol. 101, No. 3 911-919
Copyright © 1977 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WOLLHEIM, C. B.
Right arrow Articles by SHARP, G. W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WOLLHEIM, C. B.
Right arrow Articles by SHARP, G. W. G.

Somatostatin Inhibition of Pancreatic Glucagon Release from Monolayer Cultures and Interactions with Calcium

CLAES B. WOLLHEIM, BENIGNA BLONDEL, ALBERT E. RENOLD and GEOFFREY W. G. SHARP

Institut de Biochimie Clinique, and Institut d'Histologie et d'Embryologie, Université de Genève, Geneva, Switzerland

Abstract

The effects of somatostatin (SRIF) on glucagon release have been studied in the monolayer culture of newborn rat pancreas. It was found that SRIF inhibited glucagon release rapidly and in a dose dependent manner at concentrations of 1–1000 ng/ml. SRIF inhibited glucagon release under basal conditions and after stimulation by arginine, 3-isobutyl-l-methylxanthine (IBMX), high Ca++ concentrations, ionophore A23187 and Ca++, and Ba++. SRIF inhibited ionophore- induced glucagon release over 60 min when a low concentration of A23187 was used (0.1 µg/ml) but not when a high concentration (10 µg/ml) was used. The stimulant effect of 10 µg/ml A23187 was, however, inhibited by SRIF during short periods of incubation. The per cent inhibition of argininestimulated glucagon release due to SRIF remained unchanged when the Ca++ concentration in the medium was varied from 1–10 mM.

It is concluded that SRIF promptly inhibits glucagon release under basal conditions or when stimulated by a variety of agents. Thus, the action of SRIF appears to be basic to the granule release process and not specifically antagonistic to any particular stimulants. Further, as SRIF inhibits release due to raised cytosol Ca++ (e.g., ionophore- Ca++ or high Ca++ experiments) the action is probably at a late point in the release mechanism.

Footnotes

Supported by the Swiss National Science Foundation kraut nos. 3.1060.73, 3.0280.73 and 3.553.75).

Received February 2, 1977.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1977 by The Endocrine Society